Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma

The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

(2012) Gholamreza Safaee Ardekani et al.   PLoS One

Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A

(2011) Imanol Arozarena et al.   CANCER CELL

Genetic alterations of PTEN in human melanoma

(2011) Almass-Houd Aguissa-Touré et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

(2011) A. Vultur et al.   CLINICAL CANCER RESEARCH

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail

(2010) Gajanan S. Inamdar et al.   BIOCHEMICAL PHARMACOLOGY

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice

(2009) V K Goel et al.   ONCOGENE